Long-Term Outcome Following Coronary Artery Stenting by History of Preterm Delivery.
major adverse cardiovascular events
percutaneous coronary intervention
preterm delivery
Journal
JACC. Advances
ISSN: 2772-963X
Titre abrégé: JACC Adv
Pays: United States
ID NLM: 9918419284106676
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
18
07
2022
revised:
28
09
2022
accepted:
30
09
2022
medline:
30
11
2022
pubmed:
30
11
2022
entrez:
28
6
2024
Statut:
epublish
Résumé
Women are at a greater risk of a major adverse cardiovascular event (MACE) after percutaneous coronary intervention than men. A history of preterm delivery is a female-specific risk factor for coronary artery disease, but its relevance in the treatment of coronary artery disease is unknown. The purpose of this study was to analyze the association between a history of preterm delivery and MACE after the first coronary artery stenting. We included a nationwide sample of 5,766 Swedish women aged ≤65 years receiving their first coronary stent during 2006 to 2017. To adjust for periprocedural characteristics and estimate the association between a history of preterm delivery and MACE at >30 days from stenting, we used proportional hazards regression. We also investigated mortality by history of preterm delivery. During a median follow-up time of 3.7 years (IQR: 1.3-6.7 years), 1,200 (20.8%) women had a MACE. In total, 963 (16.7%) women had a history of preterm delivery. A history of preterm delivery was associated with a higher risk of MACE (adjusted HR: 1.19; 95% CI: 1.03-1.38) and mortality (adjusted HR ratio: 1.38; 95% CI: 1.02-1.85). Similar associations were observed when excluding women with a history of hypertensive disorders of pregnancy or diabetes. Subgroup analyses suggested that women with a history of early preterm delivery had lower risk of MACE than those who had late preterm delivery ( History of preterm delivery is associated with worse prognosis following the first coronary artery stenting in women and warrants consideration as a risk factor also in the secondary prevention setting.
Sections du résumé
Background
UNASSIGNED
Women are at a greater risk of a major adverse cardiovascular event (MACE) after percutaneous coronary intervention than men. A history of preterm delivery is a female-specific risk factor for coronary artery disease, but its relevance in the treatment of coronary artery disease is unknown.
Objectives
UNASSIGNED
The purpose of this study was to analyze the association between a history of preterm delivery and MACE after the first coronary artery stenting.
Methods
UNASSIGNED
We included a nationwide sample of 5,766 Swedish women aged ≤65 years receiving their first coronary stent during 2006 to 2017. To adjust for periprocedural characteristics and estimate the association between a history of preterm delivery and MACE at >30 days from stenting, we used proportional hazards regression. We also investigated mortality by history of preterm delivery.
Results
UNASSIGNED
During a median follow-up time of 3.7 years (IQR: 1.3-6.7 years), 1,200 (20.8%) women had a MACE. In total, 963 (16.7%) women had a history of preterm delivery. A history of preterm delivery was associated with a higher risk of MACE (adjusted HR: 1.19; 95% CI: 1.03-1.38) and mortality (adjusted HR ratio: 1.38; 95% CI: 1.02-1.85). Similar associations were observed when excluding women with a history of hypertensive disorders of pregnancy or diabetes. Subgroup analyses suggested that women with a history of early preterm delivery had lower risk of MACE than those who had late preterm delivery (
Conclusions
UNASSIGNED
History of preterm delivery is associated with worse prognosis following the first coronary artery stenting in women and warrants consideration as a risk factor also in the secondary prevention setting.
Identifiants
pubmed: 38939462
doi: 10.1016/j.jacadv.2022.100142
pii: S2772-963X(22)00219-8
pmc: PMC11198654
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100142Informations de copyright
© 2022 The Authors.
Déclaration de conflit d'intérêts
This work was supported by grants awarded to Simon Timpka from the 10.13039/501100004359Swedish Research Council (2019-02082); The 10.13039/501100003793Swedish Heart-Lung Foundation (20180312); public research support via the Faculty of Medicine at 10.13039/501100003252Lund University (ALF [Avtal om Läkarutbildning och Forskning]: YF-ALF, ALF project); The 10.13039/501100007687Swedish Society of Medicine (SLS-885331); The 10.13039/100008738Jeansson Foundations, Stockholm, Sweden; and 10.13039/100007435Åke Wiberg Foundation, Stockholm, Sweden. The authors have reported that they have no relationships relevant to the contents of this paper to disclose.